2015
Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts
Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts. Journal Of Clinical Investigation 2015, 125: 2677-2689. PMID: 26053664, PMCID: PMC4563691, DOI: 10.1172/jci81229.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdrenal Cortex HormonesAdultAnimalsChronic DiseaseDisease-Free SurvivalFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansKaplan-Meier EstimateLeukemiaLymphocyte DepletionMaleMiceMiddle AgedMyelodysplastic SyndromesTissue DonorsT-Lymphocyte SubsetsTransplantation ConditioningTransplantation, HomologousYoung AdultConceptsHematopoietic stem cell transplantationStem cell graftsChronic GVHDT cellsCell graftsT-cell-depleted stem cell graftsPeripheral blood stem cell graftsAllogeneic hematopoietic stem cell transplantationBlood stem cell graftsFunctional T-cell memoryT-cell-replete graftsPathogen-specific T cellsSingle-arm clinical trialT-cell recoveryVirus-specific immunityStem cell allograftsTotal body irradiationMemory T cellsStem cell transplantationT cell memoryAcute leukemia patientsHigh-risk leukemiaNaive T cellsAcute GVHDSevere GVHD
2000
Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer E. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000, 96: 2814-21. PMID: 11023516, DOI: 10.1182/blood.v96.8.2814.h8002814_2814_2821.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigen PresentationAntigens, ViralBeta 2-MicroglobulinBiopolymersCD8-Positive T-LymphocytesChildEpstein-Barr Virus InfectionsFeasibility StudiesFemaleGraft SurvivalHematologic NeoplasmsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHistocompatibility TestingHLA-A2 AntigenHLA-B7 AntigenHLA-B8 AntigenHumansKidney TransplantationLymphoproliferative DisordersMacromolecular SubstancesMaleMiddle AgedT-Lymphocyte SubsetsTissue DonorsTransplantation ConditioningTransplantation, HomologousViral LoadConceptsEBV-specific T cellsStem cell transplantationT cellsAllo-PBSCTEBV peptidesCell transplantationT lymphocytesAllogeneic peripheral blood stem cell transplantationEpstein-Barr virus–specific T lymphocytesHuman leukocyte antigen (HLA) class I tetramersEBV-specific CD8 T cellsPeripheral blood stem cell transplantationSpecific CD8 T lymphocytesUnrelated cord blood transplantationVirus-specific T lymphocytesBlood stem cell transplantationAllogeneic stem cell transplantationCD8 T cell repertoireAllo-PBSCT patientsEBV genome copiesEpstein-Barr viremiaCD8 T lymphocytesClass I tetramersCord blood transplantationPathogen-specific immunity
1998
HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders.
McGuirk JP, Seropian S, Cooper D. HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. The Cancer Journal 1998, 4: 278-86. PMID: 9815289.Peer-Reviewed Original Research